Occam Places Ann Taylor as Board Member at Comanche Biopharma
Comanche is a preclinical biopharmaceutical company developing a novel siRNA therapy for the treatment of preeclampsia. Investors include GV, F-Prime, and Population Health Partners. The company has just appointed Ann Taylor to its Board of Directors.
Ann has an extraordinary record of achievement as a clinical development professional, with a distinguished career spanning Academia and Big Pharma. She most recently served as CMO of AstraZeneca and had previously spent a decade at Novartis leading portfolio management at NIBR, following two decades at Harvard and MassGen. She currently serves on the Boards of Terns Pharmaceuticals and Unlearn, a private company applying AI to clinical trials.
Ann has an MD from Harvard Medical School.
Occam Global is an international life science executive search and leadership advisory firm dedicated to building management teams for innovative companies in the biotech, techbio, life sciences, and venture capital sectors. Our firm’s unique strength lies in our seamless access to elite talent, proven expertise in aligning exceptional business and scientific leaders with optimal opportunities, and a steadfast dedication to creating meaningful industry impact, guided by elevated ethics and enlightened aggression. Trusted by entrepreneurs, investors, and corporations worldwide, Occam Global is recognized as the premier partner for executive search and recruitment in the life sciences. Our success is rooted in establishing trust, cultivating and valuing relationships, and committing to serve as forthright and good-humored partners in realizing extraordinary ambitions.